Recently, a hospital used the world's most advanced cell immunotherapy (CAR-T) treatment to treat a patient with advanced malignant lymphoma. Two months after transfusion, most of the patient's body mass disappeared, and relevant indicators returned to normal, marking the success of treatment.
The patient was diagnosed two years ago with the diffuse large B-cell lymphoma (non-germinal center origin, ). She had been given multiple R-CHOP, EPOCH, MINE, GDP, DICE, CHOPE and other first-line or second-line chemotherapy, but the condition control is not ideal. PET-CT showed that on tonsil, bilateral neck, supraclavicular area, bilateral axillary, hilar, mediastinal, retroperitoneal area, pelvic and bilateral inguinal, there were multiple lymph nodes. Glucose metabolism was significantly increased, suggesting a wide range of tumor violations. The prognosis is very poor. The conventional treatment of the patients has no obvious effect, and the patients family members placed the last line of hope for lymphoma CAR-T cell therapy. Two months ago, the patient received autologous CD19 CAR-T cells, and a lighter cytokine storm appeared after transfusion. Two months of transfused cells, PET-CT showed that multiple mass had disappeared, and the patient reached a complete remission.
Lymphoma is a common type of malignant blood tumor, and diffuse large mature B-cell neoplasms are the most common type of non-Hodgkin lymphomas. Conventional chemotherapy can make about 50% of patients with lymphoma get long-term survival. New drugs in recent years, such as anti-CD20 monoclonal antibody, improved the prognosis of some patients with poor prognosis. But some patients with poor efficacy of chemotherapy is easy to relapse even if the application of autologous hematopoietic stem cell transplantation is used. CAR-T technology is currently the world's latest tumor treatment technology. The existing data confirms that CAR-T has a good effect for a variety of refractory and recurrent hematological malignancies, such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, etc. Approximately 40-80% of refractory and recurrent non-Hodgkin's lymphoma patients receive efficacy after receiving CAR-T treatment.
The success of CAR-T treatment for lymphoma will further promote the process of cell immunotherapy research.
Media Contact Company Name: CAR-T Contact Person: Bella Smith Email: marketing@creative-biolabs.com Phone: 6316197922 Address:45-1 Ramsey Road City: Shirley State: NY Country: United States Website: http://www.creative-biolabs.com/car-t/
See the original post:
CAR-T Cells from Creative Biolabs Help in the Treatment of Advanced Malignant Lymphoma - Digital Journal